We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Colorectal Carcinoma Tumor Budding Automatically Evaluated

By LabMedica International staff writers
Posted on 10 Sep 2018
Tumor budding, meaning a detachment of tumor cells at the invasion front of colorectal carcinoma (CRC) into single cells or clusters has been shown to correlate to an inferior clinical outcome by several independent studies.

However, the application of tumor budding by manual evaluation in routine pathology is hampered due to the use of several slightly different assessment systems, a time-consuming manual counting process and a high inter-observer variability.

Pathologists led by their colleagues at the University Medical Centre Mannheim (Mannheim, Germany) retrieved 20 whole-slide tissue specimens of formalin-fixed paraffin-embedded tumor tissue and tissue microarray (TMAs) of tumor tissue from the Medical University of Graz (Graz, Austria). More...
These cases belong to a previously published patient cohort of 381 patients (166 males, 215 females; median age 70.1 years).

The team combined classical segmentation methods (like morphological operations) and machine learning techniques (k-means and hierarchical clustering, convolutional neural networks) to reliably detect tumor buds in colorectal carcinoma samples immunohistochemically stained for pan-cytokeratin. As a possible application, they tested it on whole-slide images as well as on tissue microarrays (TMA) from the clinically well-annotated CRC cohort. The sequential sections were digitalized as whole-slide images (WSI) using a digital microscope and M8 scanner (PreciPoint GmbH, Freising, Germany).

The scientists reported that their automatic tumor budding evaluation tool detected the absolute number of tumor buds per image with a very good correlation to the manually segmented ground truth. Furthermore the automatic evaluation of whole-slide images from 20 CRC-patients, they found that neither the detected number of tumor buds at the invasion front nor the number in hotspots was associated with the nodal status. However, the number of spatial clusters of tumor buds (budding hotspots) significantly correlated to the nodal status. TMAs were not feasible for tumor budding evaluation, as the spatial relationship of tumor buds (especially hotspots) was not preserved.

The authors concluded that on the basis of a combination of image processing and machine learning, they found that not the absolute number of tumor formations classified as “tumor buds” within the infiltrative region but rather their spatial arrangement in significant hotspots and especially the number of such hotspots is clinically meaningful. Consequently, the advice for the surgical pathologist is to focus more on the spatial distribution (as kind of pattern diagnosis), rather than on the absolute number, of tumor buds. The study was published on August 28, 2018, in the journal Diagnostic Pathology.

Related Links:
University Medical Centre Mannheim
Medical University of Graz
PreciPoint

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.